All News

2070 articles, sorted by publication time.

Genomic Medicine · global

Sickle Cell Gene Therapy Moves Into Young Children, but Approval Is Only the Start of a Long Care Challenge

The U.S. FDA has allowed Vertex's sickle cell disease gene therapy to be used in children as young as two, signaling that a one-time treatment is entering the disease course earlier; but in pediatric care, the real test lies not only in efficacy, but also in pre-treatment conditioning, long-term follow-up, and family decision-making.